Meropenem Dr. Eberth

Meropenem, the active ingredient in Meropenem Dr. Eberth, is a carbapenem antibiotic presented as a sterile powder for intravenous use. It treats serious Gram‑negative and Gram‑positive bacterial infections in hospitalized patients, including those with resistant organisms.

GNH USA supplies Meropenem Dr. Eberth as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Meropenem is a broad‑spectrum carbapenem used for severe infections caused by susceptible bacteria.

- Complicated intra‑abdominal infections: provides coverage against mixed aerobic and anaerobic pathogens. - Hospital‑acquired pneumonia and ventilator‑associated pneumonia: effective against resistant Gram‑negative organisms. - Complicated urinary tract infections: treats infections caused by multidrug‑resistant Enterobacteriaceae. - Bacterial meningitis: penetrates the cerebrospinal fluid to eradicate causative bacteria. - Sepsis and febrile neutropenia: offers rapid bactericidal activity in critically ill patients.

Adverse reactions may occur with meropenem therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: may be watery and self‑limiting. - Rash: erythematous skin eruption. - Headache: transient and usually resolves. - Elevated liver enzymes: transient increase in transaminases. - Infusion site reactions: pain or phlebitis at the injection site.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or CNS disorders. - Clostridioides difficile‑associated diarrhea: can be severe and life‑threatening. - Anaphylaxis: acute hypersensitivity reaction requiring immediate treatment. - Severe neutropenia: marked reduction in white blood cells. - Thrombocytopenia: low platelet count leading to bleeding risk. - Renal toxicity: acute kidney injury in susceptible individuals.

Careful assessment and monitoring are required when using meropenem.

- Renal impairment: adjust dose based on creatinine clearance. - Hypersensitivity: avoid in patients with known carbapenem or β‑lactam allergy. - Neonates and infants: use only under specialist supervision. - Seizure risk: monitor neurologic status, especially in patients with CNS disorders. - Concomitant valproic acid: may reduce serum valproate levels, increasing seizure risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Meropenem may interact with other medicines, requiring vigilance.

Major Interactions (Avoid): - Valproic acid: meropenem reduces valproate levels, risking seizure breakthrough. - Other carbapenems: additive neurotoxicity, especially seizures. - Aminoglycosides: combined nephrotoxic potential.

Moderate Interactions (Monitor Closely): - Warfarin: may alter INR, requiring coagulation monitoring. - Oral contraceptives: possible reduction in efficacy, advise backup contraception. - Loop diuretics: may enhance renal clearance, adjust dosing if needed.